About RIA business

Scripbox offers a fee-based Investment advisory model under SEBI Registered Investment Adviser License through its subsidiary: Mitraz Financial Services Pvt Ltd. Mitraz was one of India's first fee-based investment advisors, with a solid track record of professional and competent investment advisory. Bringing you the best of human experience combined with the best of science, for superior outcomes.

Team with over 2 decades of experience

10+ years in the RIA business

Pioneering institutional RIA service provider

Personalised asset allocation for your needs & risk profile

Don't just take our word for it

Premjith Alampilly, 42

COD, Gritstone Technologies

As a wealth manager, Scripbox's interest has been understanding my wealth goals, empathising with them and then suggesting how they can be achieved. They have been the other self i wanted in me, that takes care of my finances.

Ravi Balakrishnan, 50

Head of Sales and Marketing, Automotive Component Industry

Scripbox offers wealth management at its best - automated with a human touch.

Sumit Mehra, 43

Principal Group Product Manager, Microsoft

It was not until almost one to one and a half years of investment that I stumbled upon Scripbox. But I just took the leap of faith and never looked back since. I think of Scripbox more like a buddy or a partner, who is just there and doing the right job.

We are a SEBI Registered Investment Adviser
with high standards of Customer Satisfaction

Complaints Disclosure

At the beginning of the month Received during the month Resolved during the month Pending at the end of the month Reasons for pendency
0 0 0 0 Not Applicable

* Displaying SEBI registered complaints as per latest SEBI guideline

Compliance Audit Status

S. No. Financial Year Compliance Audit Status Remarks (if any)
1 FY2020-21 Conducted
Report Link		 NA
2 FY2021-22 Conducted
Report Link		 NA
3 FY2022-23 Conducted
Report Link		 NA
4 FY2023-24 Conducted
Report Link		 Audit report submitted to BASL on 30th Sep 2024. We will send status update on the adverse findings before 31st Oct 2024.